血管紧张素转换酶抑制剂在IgA肾病治疗中的临床应用研究  

The Clinical Study of Angiotensin-converting Enzyme Inhibitor in IgA Nephropathy

作　　者：刘宏伟[1] 

机构地区：[1]湖北省松滋市人民医院肾内科,434200

出　　处：《临床合理用药杂志》2011年第01X期22-23,共2页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的观察血管紧张素转换酶抑制剂(ACEI)治疗IgA肾病的临床效果。方法收集本科就诊的IgA肾病患者65例,随机分为治疗组和对照组。治疗组应用ACEI类药物贝那普利(10mg/d)治疗;对照组给予非ACEI类降压药治疗。对患者治疗前后的尿蛋白、血清清蛋白、血脂、血肌酐、内生肌酐清除率及血压等指标进行监测。结果治疗3个月后治疗组患者的尿蛋白水平显著下降(P<0.01),血清清蛋白显著升高(P<0.01),血脂、血肌酐和肌酐清除率等治疗前后无明显变化。对照组治疗3个月后各项指标与治疗前比较差异无统计学意义(P>0.05)。结论 ACEI类药物可以减轻IgA肾病患者的蛋白尿,保护此类患者的肾功能。Objective To investigate the effects of angiotensin-converting enzyme inhibitor （ACEI） on IgA nephropathy.Methods 65 cases with IgA nephropathy diagnosed by renal biopsy were randomly divided into two groups： ACEI group （benazepril 10 mg/ d） and control group.The albuminuria,lipids,blood pressure,and serum creatinine were monitored before and after treatment.Adverse reactions durin the study were also recorded.Results After treatment of ACEI,the levels of albuminuria decreased significantly in patients with IgA nephropathy （ P〈0.01）.While in the control group the proteinuria level increased and the clearance of creatinine decreased continuously during the observation （P〈0.01）.Conclusion It is suggested that ACEI could definitely reduce albuminuria and protect renal function of patients with IgA nephropathy.

关 键 词：IGA肾病 血管紧张素转换酶抑制剂 尿蛋白 

分 类 号：R692.3[医药卫生—泌尿科学]